白三烯受体拮抗剂治疗慢阻肺继发肺间质纤维化的临床疗效观察

Observation of clinical effect of leukotriene receptor antagonist in the treatment of patients with PF-COPD

目的评价白三烯受体拮抗剂对治疗慢阻肺继发肺间质纤维化(PF-COPD)的临床疗效。方法将40例PF-COPD患者随机分为观察组20例和治疗组20例,实验中两组均予常规治疗(包括氧疗、祛痰、肺功能锻炼与支气管扩张剂等),治疗组在此基础上加服顺尔宁每日1粒,连续应用3个月。观察全部病例用药前及用药后3个月的:临床症状改善、血气分析、肺功能、HRCT等变化。结果与治疗前相比,治疗组患者3个月后的呼吸困难评分及运动耐力显著改善,与对照组相比差异有显著性(P<0.05);同时治疗组患者治疗前后PaO2、VC%、FEV1%pred、DLC0%均明显改善,对照组则无明显变化,两组差异亦具有显著性(P<0.05)。结论顺尔宁治疗PF-COPD有效和可行。

Objective To evaluate the therapeutic effect of leukotriene receptor antagonist （ Montelukast Sodium Chewable Tab- lets, Shun Erning） in the treatment of patients with PF-COPD. Methods 40 patients with PF-COPD were all given conventional treat- ment, including oxygen therapy, reduc＇e phlegm, pulmonary function exercises and salbutamol inhalation, and then they were randomly and evenly divided into two groups. The treatment group was additionally treated with 1 tablet of Shun Erning everyday for 3 months. The changes of clinical symptoms, blood gas analysis, pulmonary function and HRCT image were observed before and 3 months after the treat- ment. Results After the treatment, the improvement of dyspnea scores and exercise tolerance was more pronounced in the treatment group than in the control group with significant difference （P 〈 0. 05 ）. The levels of PaO2 , VC% , FEV1% pred and DLCO% of the treatment group were significantly improved 3 months after the treatment （ P 〈 0. 05 ）, but there was no significant difference in the control group before and 3 months after the treatment （P 〉 0.05 ）. Conclusion Leukotriene receptor antagonist is and effective and feasible method in the treatment of patients with PF-COPD.